Homo and Heterodimer Ligands: The Twin Drug Approach

The Practice of Medicinal Chemistry

Volumn , Issue , 2008, Pages 380-414

  Contreras, Jean Marie ^a   Sippl, Wolfgang ^b  

^a Prestwick Chemical Inc   (France)

^b MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882514088     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-374194-3.00018-4     Document Type: Chapter

References (132)

1. Contreras J.M., Bourguignon J.J. Identical and non-identical twin drugs. The Practice of Medicinal Chemistry 2003, 251-273. Academic Press, London. C.G. Wermuth (Ed.).
2. Morphy R., Kay C., Rankovic Z. From magic bullets to designed multiple ligands. Drug Discov. Today 2004, 9:641-651.
3. Morphy R., Rankovic Z. Designed multiple ligands. An emerging drug discovery paradigm. J. Med. Chem. 2005, 48:6523-6543.
4. Csermely P., Agoston V., Pongor S. The efficiency of multi-target drugs: the network approach might help drug design. Trends Pharmacol. Sci. 2005, 26:178-182.
5. Mencher S.K., Wang L.G. Promiscuous drugs compared to selective drugs (promiscuity can be a virtue). BMC Clin. Pharmacol. 2005, 5:3.
6. Sams-Dodd F. Target-based drug discovery: is something wrong?. Drug Discov. Today, 2005, 10:139-147.
7. Frantz S. Drug discovery: playing dirty. Nature, 2005, 437:942-943.
8. Morphy R., Rankovic Z. The physicochemical challenges of designing multiple ligands. J. Med. Chem. 2006, 49:4961-4970.
9. Espinoza-Fonseca L.M. The benefits of the multi-target approach in drug design and discovery. Bioorg. Med. Chem. 2006, 14:896-897.
10. Morphy R., Rankovic Z. Fragments, network biology and designing multiple ligands. Drug Discov. Today, 2007, 12:156-160.
11. Pang Y.-P., Quiram P., Jelacic T., Hong F., Brimijoin S. Highly potent, selective, and low cost bis-tetrahydroaminacrine inhibitors of acetylcholinesterase. J. Biol. Chem. 1996, 271:23646-23649.
12. Hu M.K., Wu L.J., Hsiao G., Yen M.H. Homodimeric tacrine congeners as acetylcholinesterase inhibitors. J. Med. Chem. 2002, 45:2277-2282.
13. Baldwin J.J., Lumma W.C., Lundell G.F., Ponticello G.S., Raab A.W., Engelhardt E.L., Hirschmann R., Sweet C.S., Scriabine A. Symbiotic approach to drug design: antihypertensive β-adrenergic blocking agents. J. Med. Chem. 1979, 22:1284-1290.
14. Cecchetti V., Fravolini A., Schiaffella F., Tabarrini O., Bruni G., Segre G. o-Chlorobenzenesulfonamidic derivatives of (aryloxy)propanolamines as β-blocking/diuretic agents. J. Med. Chem. 1993, 36:157-161.
15. Murugesan N., Gu Z., Fadnis L., Tellew J.E., Baska R.A., Yang Y., Beyer S.M., Monshizadegan H., Dickinson K.E., Valentine M.T., Humphreys W.G., Lan S.J., Ewing W.R., Carlson K.E., Kowala M.C., Zahler R., Macor J.E. Dual angiotensin II and endothelin A receptor antagonists: synthesis of 2'-substituted N-3-isoxazolyl biphenylsulfonamides with improved potency and pharmacokinetics. J. Med. Chem. 2005, 48:171-179.
16. Piwinski J.J., Wong J.K., Green M.J., Ganguly A.K., Billah M.M., West R.E., Kreutner W. Dual antagonists of platelet activating factor and histamine. Identification of structural requirements for dual activity of N-acyl-4-(5,6-dihydro-11H-benzo[5,6]cyclohepta-[1,2-b]pyridin-11-ylene) piperidines. J. Med. Chem. 1991, 34:457-461.
17. Stephenson V.C., Heyding R.A., Weaver D.F. The "promiscuous drug concept" with applications to Alzheimer's disease. FEBS Lett. 2005, 579:1338-1342.
18. Changeux J.P. Remarks on the symmetry and cooperative properties of biological membranes. Symmetry and Function of Biological Systems at the Macromolecular Level 1969, 235-256. Almqvist and Wiksell, Stockholm. A. Engström, B. Strandberg (Eds.).
19. Blundell T., Sewell T., Turnell B. Symmetry in the structure and organization of proteins. Structural Studies on Molecules of Biological Interest 1981, 390-403. Oxford University Press, London. G. Dodson, J.P. Glusker, D. Sayre (Eds.).
20. Sidddle K. The insulin receptor. Receptor Subunits and Complexes 1992, 261-351. Cambridge University Press, Cambridge. A. Burgen, E.A. Barnard (Eds.).
21. Ariëns E.J. Drug design: a general introduction. Drug Design 1971, Vol. 1:1-270. Academic Press, New York. E.J. Ariëns (Ed.).
22. Bell M.R., Batzold F.H., Winneker R.C. Chemical control of fertility. Annual Reports in Medicinal Chemistry 1986, Vol. 21:169-177. Academic Press, San Diego. D.M. Bailey (Ed.).
23. Neupert-Laves K., Dobber M. The crystal structure of a K+ complex of valinomycin. Helv. Chim. Acta. 1975, 58:432-442.
24. Tamiz A.P., Bandyopadhyay B.C., Zhang J., Flippen-Anderson J.L., Zhang M., Wang C.Z., Johnson K.M., Tella S., Kozikowski A.P. Pharmacological and behavioral analysis of the effects of some bivalent ligand-based monoamine reuptake inhibitors. J. Med. Chem. 2001, 44:1615-1622.
25. Kierstead R.W., Faraone A., Mennona F., Mullin J., Guthrie R.W., Crowley H. Beta-1-selective adrenoceptor antagonists. Blocking activity of a series of binary (aryloxy) propanolamines. J. Med. Chem. 1983, 26:1561-1569.
26. 2 muscarinic receptor antagonists. J. Med. Chem. 1993, 36:3734-3737.
27. Rosini M., Budriesi R., Bixel M.G., Bolognesi M.L., Chiarini A., Hucho F., Krogsgaard-Larsen P., Mellor I.R., Minarini A., Tumiatti V., Usherwood P.N.R., Melchiorre C. Design, synthesis, and biological evaluation of symmetrically and unsymmetrically substituted methoctramine-related polyamines as muscular nicotinic receptor noncompetitive antagonists. J. Med. Chem. 1999, 42:5212-5223.
28. Rosini M., Bixel M.G., Marucci G., Budriesi R., Krauss M., Bolognesi M.L., Minarini A., Tumiatti V., Hucho F., Melchiorre C. Structure-activity relationships of methoctramine-related polyamines as muscular nicotinic receptor noncompetitive antagonists. 2. Role of polymethylene chain lengths separating amine functions and of substituents on the terminal nitrogen atoms. J. Med. Chem. 2002, 45:1860-1878.
29. Wei Z.L., Xiao Y., Kellar K.J., Kozikowski A.P. Synthesis and pharmacological characterization of bivalent ligands of epibatidine at neuronal nicotinic acetylcholine receptors. Bioorg. Med. Chem. Lett. 2004, 14:1855-1858.
30. Roth R.A., Cassell D.J., Morgan D.O., Tatnell M.A., Jones R.H., Schüttler A., Brandenburg D. Effects of covalently linked insulin dimers on receptor kinase activity and receptor down regulation. FEBS Lett. 1984, 170:360-364.
31. 11-24 on steroidogenesis by synthesis of covalent dimeric conjugates. FEBS Lett. 1985, 183:283-286.
32. Chino N., Yoshizawa-Kumagaye K., Noda Y., Watanabe T.X., Kimura T., Sakakibara S. Synthesis and biological properties of antiparrallel and parallel dimers of human α-human atrial natriuretic peptide. Biochem. Biophys. Res. Comm. 1986, 141:665-672.
33. 2 receptor. J. Med. Chem. 1993, 36:2583-2584.
34. Costa T., Wüster M., Herz A., Shimohigashi Y., Chen H.-C., Rodbard D. Receptor binding and biological activity of bivalent enkephalins. Biochem. Pharmacol. 1985, 34:25-30.
35. Portoghese P.S., Larson D.L., Sayre L.M., Yim C.B., Ronsisvalle G., Tam S.W., Takemori A.E. Opioid agonist and antagonist bivalent ligands. The relationship between spacer length and selectivity at multiple opioid receptors. J. Med. Chem. 1986, 29:1855-1861.
36. Lin C.-E., Takemori A.E., Portoghese P.S. Synthesis and κ-opioid antagonist selectivity of a norbinaltorphimine congener. Identification of the address moiety required for #61472; κ-antagonist activity. J. Med. Chem. 1993, 36:2412-2415.
37. Portoghese P.S. Bivalent ligands and the message-address concept in the design of selective opioid receptor antagonists. Trends Pharmacol. Sci. 1989, 10:230-235.
38. Joslyn A.F., Luchowski E., Triggle D.J. Dimeric 1,4-dihydropyridines as calcium channel antagonists. J. Med. Chem. 1988, 31:1489-1492.
39. Descamps-Francois C., Yous S., Chavatte P., Audinot V., Bonnaud A., Boutin J.A., Delagrange P., Bennejean C., Renard P., Lesieur D. Design and synthesis of naphthalenic dimers as selective MT1 melatoninergic ligands. J. Med. Chem. 2003, 46:1127-1129.
40. Sauerberg P., Bury P.S., Mogensen J.P., Deussen H.J., Pettersson I., Fleckner J., Nehlin J., Frederiksen K.S., Albrektsen T., Din N., Svensson L.A., Ynddal L., Wulff E.M., Jeppesen L. Large dimeric ligands with favorable pharmacokinetic properties and peroxisome proliferator-activated receptor agonist activity in vitro and in vivo. J. Med. Chem. 2003, 46:4883-4894.
41. De Clerq E. Toward improved anti-HIV chemotherapy: therapeutic strategies for intervention with HIV infections. J. Med. Chem. 1995, 38:2491-2517.
42. Appelt K. Crystal structures of HIV-1 protease-inhibitor complexes. Persp. Drug Discov. Des. 1993, 1:23-48.
43. 2 symmetry. J. Am. Chem. Soc. 1991, 113:9382-9384.
44. Tan G.T., Wickramasinghe A., Verma S., Singh R., Hughes S.H., Pezzuto J.M., Baba M., Mohan P. Potential anti-AIDS naphtalenesulfonic acid derivatives. Synthesis and inhibition of HIV-1 induced cytopathogenesis and HIV-1 and HIV-2 reverse transcriptase activity. J. Med. Chem. 1992, 35:4846-4853.
45. 2 symmetric inhibitor complexed to HIV-1 protease. Science 1990, 249:527-533.
46. Hulten J., Bonham N.M., Nillroth U., Hansson T., Zuccarello G., Bouzide A., Aqvist J., Classon B., Danielson U.H., Karlen A., Kvarnstrom I., Samuelsson B., Hallberg A. Cyclic HIV-1 protease inhibitors derived from mannitol: synthesis, inhibitory potencies, and computational predictions of binding affinities. J. Med. Chem. 1997, 40:885-897.
47. 2-symmetric HIV-1 protease inhibitors. Use of the l-mannaric acid as a peptidomimetic scaffold. J. Med. Chem. 1998, 41:3782-3792.
48. Sridhar J., Wei Z.L., Nowak I., Lewin N.E., Ayres J.A., Pearce L.V., Blumberg P.M., Kozikowski A.P. New bivalent PKC ligands linked by a carbon spacer: enhancement in binding affinity. J. Med. Chem. 2003, 46:4196-4204.
49. Qin D., Sullivan R., Berkowitz W.F., Bittman R., Rotenberg S.A. Inhibition of protein kinase Cα by dequalinium analogues: depen-dence on the linker length and geometry. J. Med. Chem. 2003, 43:1413-1417.
50. Rossello A., Nuti E., Catalani M.P., Carelli P., Orlandini E., Rapposelli S., Tuccinardi T., Atkinson S.J., Murphy G., Balsamo A. A new development of matrix metalloproteinase inhibitors: twin hydroxamic acids as potent inhibitors of MMPs. Bioorg. Med. Chem. Lett. 2005, 15:2311-2314.
51. Shaw K.J., Guilford W.J., Dallas J.L., Koovakkaat S.K., McCarrick M.A., Liang A., Light D.R., Morrissey M.M. (Z,Z)-2,7-Bis(4-amidinobenzylidene)cycloheptan-1-one: identification of a highly active inhibitor of blood coagulation factor Xa. J. Med. Chem. 1998, 41:3551-3556.
52. Phillips G., Davey D.D., Eagen K.A., Koovakkat S.K., Liang A., Ng H.P., Pinkerton M., Trinh L., Whitlow M., Beatty A.M., Morrissey M.M. Design, synthesis, and activity of 2,6-diphenoxypyridine-derived factor Xa inhibitors. J. Med. Chem. 1999, 42:1749-1756.
53. Stanek J., Caravatti G., Capraro H.-G., Furet P., Mett H., Schneider P., Regenass U. S-Adenosylmethionine decarboxylase inhibitors: new aryl and heteroaryl analogues of methylglyoxal bis(guanylhydrazone). J. Med. Chem. 1993, 36:46-54.
54. Taylor P., Lappi S. Interaction of fluorescence probes with acetylcholinesterase. The site and specificity of propidium binding. Biochemistry 1975, 14:1989-1997.
55. Fairley T.A., Tidwell R.R., Donkor I., Naiman N.A., Ohemeng K.A., Lombardy R.J., Bentley J.A., Cory M. Structure, DNA minor groove binding, and base pair specificity of alkyl- and aryl-linked bis(amidinobenzimidazoles) and bis(amidinoindoles). J. Med. Chem. 1993, 36:1746-1753.
56. Gamage S.A., Spicer J.A., Atwell G.J., Finlay G.J., Baguley B.C., Denny W.A. Structure-activity relationships for substituted bis(acridine-4-carboxamides): a new class of anticancer agents. J. Med. Chem. 1999, 42:2383-2393.
57. Vennerström J.L., Ellis W.Y., Ager A.L., Anderson S.L., Gerena L., Milhous W.K. Bisquinolines. 1. N,N-bis(7-Chloroquinolin-4-yl) alkanediamines with potential against chloroquine-resistant malaria. J. Med. Chem. 1992, 35:2129-2134.
58. Girault S., Grellier P., Berecibar A., Maes L., Mouray E., Lemière P., Debreu M.-A., Davioud-Charvet E., Sergheraert C. Antimalarial, antitrypanosomal, and antileishmanial activities and cytotoxiciy of bis(9-amino-6-chloro-2-methoxyacridines): influence of the linker. J. Med. Chem. 2000, 43:2646-2654.
59. 2 receptors. J. Med. Chem. 1993, 36:1488-1495.
60. Lowe III J.A., Seeger T.F., Nagel A.A., Howard H.R., Seymour P.A., Heym J.H., Ewing F.E., Newman M.E., Schmidt A.W., Furman J.S., et al. 1-Naphthylpiperazine derivatives as potential atypical antipsychotic agents. J. Med. Chem. 1991, 34:1860-1866.
61. Howard H.R., Lowe III J.A., Seeger T.F., Seymour P.A., Zorn S.H., Maloney P.R., Ewing F.E., Newman M.E., Schmidt A.W., Furman J.S., Robinson G.L., Jackson E., Johnson C., Morrone J. 3-Benzisothiazolylpiperazine derivatives as potential atypical anti-psychotic agents. J. Med. Chem. 1996, 39:143-148.
62. Buschauer A. Synthesis and in vitro pharmacology of arpromidine and related phenyl(pyridylalkyl)guanidines, a potential new class of positive inotropic drugs. J. Med. Chem. 1989, 32:1963-1970.
63. 1 dual antagonizing activity 1. J. Med. Chem. 1993, 36:417-420.
64. Zhang J.C., Entzeroth M., Wienen W. Characterization of BIBS 39 and BIBS 222: two new non peptide angiotensine II receptor antagonists. Eur. J. Pharmacol. 1992, 218:35-41.
65. de Laszlo S.E., Quagliato C.S., Greenlee W.J., Patchett A.A., Chang R.S., Lotti V.J., Chen T.B., Scheck S.A., Faust K.A., Kivlighn S.S., et al. A potent, orally active balanced affinity angio-tensin II AT1 antagonist and AT2 binding inhibitor. J. Med. Chem. 1993, 36:3207-3210.
66. Ikeda T., Ohta H., Okada M., Kawai N., Nakao R., Siegl P.K., Kobayashi T., Miyauchi T., Nishikibe M. Antihypertensive effects of a mixed endothelin-A- and -B-receptor antagonist, J-104132, were augmented in the presence of an AT1-receptor antagonist, MK-954. J. Cardiovasc. Pharmacol. 2000, 36:S337-S341.
67. Bohlender J., Gerbaulet S., Kramer J., Gross M., Kirchengast M., Dietz R. Synergistic effects of AT(1) and ET(A) receptor blockade in a transgenic, angiotensin II-dependent, rat model. Hypertension, 2000, 35:992-997.
68. Murugesan N., Tellew J.E., Gu Z., Kunst B.L., Fadnis L., Cornelius L.A., Baska R.A., Yang Y., Beyer S.M., Monshizadegan H., Dickinson K.E., Panchal B., Valentine M.T., Chong S., Morrison R.A., Carlson K.E., Powell J.R., Moreland S., Barrish J.C., Kowala M.C., Macor J.E. Discovery of N-isoxazolyl biphenylsulfonamides as potent dual angiotensin II and endothelin A receptor antagonists. J. Med. Chem. 2002, 45:3829-3835.
69. Jacobson K.A., Lipkowski A.W., Moody T.W., Padgett W., Pijl E., Kirk K.L., Daly J.W. Binary drugs: conjugates of purines and a peptide that bind to both adenosine and substance P. J. Med. Chem. 1987, 30:1529-1532.
70. Willson T.M., Brown P.J., Sternbach D.D., Henke B.R. The PPARs: from orphan receptors to drug discovery. J. Med. Chem. 2000, 43:527-550.
71. Brooks D.A., Etgen G.J., Rito C.J., Shuker A.J., Dominianni S.J., Warshawsky A.M., Ardecky R., Paterniti J.R., Typhonas J., Karanewsky D.S., Kauffman R.F., Broderick C.L., Oldham B.A., Montrose-Rafizadeh C., Winneroski L.L., Faul M.M., McCarthy J.R. Design and synthesis of 2-methyl-2-(4-[2-(5-methyl-2-aryloxazol-4-yl)ethoxy]phenoxy)propionic acids: a new class of dual PPARα/γ agonists. J. Med. Chem. 2001, 44:2061-2064.
72. Kasuga J., Yamasaki D., Araya Y., Nakagawa A., Makishima M., Doi T., Hashimoto Y., Miyachi H. Design, synthesis, and evaluation of a novel series of alpha-substituted phenylpropanoic acid derivatives as human peroxisome proliferator-activated receptor (PPAR) alpha/delta dual agonists for the treatment of metabolic syndrome. Bioorg. Med. Chem. 2006, 14:8405-8414.
73. Unangst P.C., Connor D.T., Cetenko W.A., Sorenson R.J., Kostlan C.R., Sircar J.C., Wright C.D., Schrier D.J., Dyer R.D. Synthesis and biological evaluation of 5-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]methylene]oxazoles, -thiazoles, and imid-azoles: novel dual 5-lipoxygenase and cyclooxygenase inhibitors with antiinflammatory activity. J. Med. Chem. 1994, 37:322-328.
74. Barbey S., Goossens L., Taverne T., Cornet J., Choesmel V., Rouaud C., Gimeno G., Yannic-Arnoult S., Michaux C., Charlier C., Houssin R., Henichart J.P. Synthesis and activity of a new methoxytetrahydropyran derivative as dual cyclooxygenase-2/5-lipoxygenase inhibitor. Bioorg. Med. Chem. Lett. 2002, 12:779-782.
75. Flynn G.A., Beight D.W., Mehdi S., Koehl J.R., Giroux E.L., French J.F., Hake P.W., Dage R.C. Application of a conformationally restricted phe-leu dipeptide mimetic to the design of a combined inhibitor of angiotensin I-converting enzyme and neutral endopeptidase 24.11. J. Med. Chem. 1993, 36:2420-2423.
76. Robl J.A., Sun C.Q., Stevenson J., Ryono D.E., Simpkins L.M., Cimarusti M.P., Dejneka T., Slusarchyk W.A., Chao S., Stratton L., Misra R.N., Bednarz M.S., Asaad M.M., Cheung H.S., Abboa-Offei B.E., Smith P.L., Mathers P.D., Fox M., Schaeffer T.R., Seymour A.A., Trippodo N.C. Dual metalloprotease inhibitors: mercaptoacetyl-based fused heterocyclic dipeptide mimetics as inhibitors of angiotensin-converting enzyme and neutral endopeptidase. J. Med. Chem. 1997, 40:1570-1577.
77. Pontikis R., Dollé V., Guillaumel J., Dechaux E., Note R., Nguyen C.H., Legraverend M., Bisagni E., Aubertin A.-M., Grierson D.S., Monneret C. Synthesis and evaluation of "AZT-HEPT", "AZT-pyridinone", and "ddC-HEPT" conjugates as inhibitors of HIV reverse transcriptase. J. Med. Chem. 2000, 43:1927-1939.
78. Camps P., El Achab R., Gorbig D.M., Morral J., Munoz-Torrero D., Badia A., Banos J.E., Vivas N.M., Barril X., Orozco M., Luque F.J. Synthesis, in vitro pharmacology, and molecular modeling of very potent tacrine-huperzine A hybrids as acetylcholinesterase inhibitors of potential interest for the treatment of Alzheimer's disease. J. Med. Chem. 1999, 42:3227-3242.
79. Mary A., Renko D.Z., Guillou C., Thal C. Potent acetylcholines-terase inhibitors: design, synthesis, and structure-activity relationships of bis-interacting ligands in the galanthamine series. Bioorg. Med. Chem. 1998, 6:1835-1850.
80. Van der Schyf C.J., Geldenhuys W.J., Youdim M.B. Multifunctional drugs with different CNS targets for neuropsychiatric disorders. J. Neurochem. 2006, 99:1033-1048.
81. Kogen H., Toda N., Tago K., Marumoto S., Takami K., Ori M., Yamada N., Koyama K., Naruto S., Abe K., Yamazaki R., Hara T., Aoyagi A., Abe Y., Kaneko T. Design and synthesis of dual inhibitors of acetylcholinesterase and serotonin transporter targeting potential agents for Alzheimer's disease. Org. Lett. 2002, 4:3359-3362.
82. Toda N., Tago K., Marumoto S., Takami K., Ori M., Yamada N., Koyama K., Naruto S., Abe K., Yamazaki R., Hara T., Aoyagi A., Abe Y., Kaneko T., Kogen H. Design, synthesis and structure-activity relationships of dual inhibitors of acetylcholinesterase and sero-tonin transporter as potential agents for Alzheimer's disease. Bioorg. Med. Chem. 2003, 11:1935-1955.
83. Toda N., Tago K., Marumoto S., Takami K., Ori M., Yamada N., Koyama K., Naruto S., Abe K., Yamazaki R., Hara T., Aoyagi A., Abe Y., Kaneko T., Kogen H. A conformational restriction approach to the development of dual inhibitors of acetylcholinesterase and serotonin transporter as potential agents for Alzheimer's disease. Bioorg. Med. Chem. 2003, 11:4389-4415.
84. 2 receptor antagonists and synthetase inhibitors. J. Med. Chem. 1994, 37:26-39.
85. 2 receptor antagonists and synthase inhibitors. J. Med. Chem. 1999, 42:1235-1249.
86. 2 synthase inhibition. J. Med. Chem. 1993, 36:2964-2972.
87. Fujita M., Seki T., Inada H., Shimizu K., Takahama A., Sano T. Approach to dual-acting platelet activating factor (PAF) receptor antagonist/thromboxane synthase inhibitor (TxSI) based on the link of PAF antagonists and TxSIs. Bioorg. Med. Chem. Lett. 2002, 12:341-344.
88. Allan G., Cambridge D., Hardy G.W., Follenfant M.J. BW A575C a chemically novel agent with angiotensin converting enzyme inhibitor and beta-adrenoceptor-blocking properties. Br. J. Pharmacol. 1987, 90:609-615.
89. Cecchetti V., Schiaffella F., Tabarrini O., Zhou W., Fravolini A., Goi A., Bruni G., Segre G. Symbiotic approach to drug design: N-[(4-Chloro-3-sulfamoylbenzamido)ethyl]propanolamine derivatives as beta-adrenergic blocking agents with diuretic activity. Eur. J. Med. Chem. 1991, 26:381-386.
90. Albrecht H.A., Beskid G., Christenson J.G., Deitcher K.H., Georgopapadakou N.H., Keith D.D., Konzelmann F.M., Pruess D.L., Wei C.C. Dual-action cephalosporins incorporating a 3'-tertiary-amine-linked quinolone. J. Med. Chem. 1994, 37:400-407.
91. 1A serotonin receptors and serotonin transporter as a new class of antidepressants. J. Med. Chem. 2001, 44:418-428.
92. Matzen L., van Amsterdam C., Rautenberg W., Greiner H.E., Harting J., Seyfriend C.A., Bottcher H. 5-HT reuptake inhibitors with 5-HT1B/1D antagonistic activity: a new approach toward efficient antidepressants. J. Med. Chem. 2000, 43:1149-1157.
93. Ocampo M.T., Chaung W., Marenstein D.R., Chan M.K., Altamirano A., Basu A.K., Boorstein R.J., Cunningham R.P., Teebor G.W. Targeted deletion of mNth1 reveals a novel DNA repair enzyme activity. Mol. Cell. Biol. 2002, 22:6111-6121.
94. Papp B., Pal C., Hurst L.D. Metabolic network analysis of the causes and evolution of enzyme dispensability in yeast. Nature, 2004, 429:661-664.
95. Sussman J.L., Harel M., Frolow F., Oefner C., Goldman A., Toker L., Silman I. Atomic structure of acetylcholinesterase from Torpedo californica: a prototypic acetylcholine-binding protein. Science 1991, 253:872-879.
96. Silman I., Sussman J.L. Acetylcholinesterase: "classical" and "non-classical" functions and pharmacology. Curr. Opin. Pharmacol. 2005, 5:293-302.
97. Du D.M., Carlier P.R. Development of bivalent acetylcholines-terase inhibitors as potential therapeutic drugs for Alzheimer's disease. Curr. Pharm. Des. 2004, 10:3141-3156.
98. Sippl W., Contreras J.M., Parrot I., Rival Y.M., Wermuth C.G. Structure-based 3D QSAR and design of novel acetylcholinesterase inhibitors. J. Comput. Aided Mol. Des. 2001, 15:395-410.
99. Rydberg E.H., Brumshtein B., Greenblatt H.M., Wong D.M., Shaya D., Williams L.D., Carlier P.R., Pang Y.P., Silman I., Sussman J.L. Complexes of alkylene-linked tacrine dimers with Torpedo californica acetylcholinesterase: Binding of Bis5-tacrine produces a dramatic rearrangement in the active-site gorge. J. Med. Chem. 2006, 49:5491-5500.
100. Greenblatt H.M., Guillou C., Guenard D., Argaman A., Botti S., Badet B., Thal C., Silman I., Sussman J.L. The complex of a bivalent derivative of galanthamine with torpedo acetylcholines-terase displays drastic deformation of the active-site gorge: implications for structure-based drug design. J. Am. Chem. Soc. 2004, 126:15405-15411.
101. Barril X., Orozco M., Luque F.J. Predicting relative binding free energies of tacrine-huperzine A hybrids as inhibitors of acetylcholinesterase. J. Med. Chem. 1999, 42:5110-5119.
102. De Ferrari G.V., Canales M.A., Shin I., Weiner L.M., Silman I., Inestrosa N.C. A structural motif of acetylcholinesterase that promotes amyloid beta-peptide fibril formation. Biochemistry, 2001, 40:10447-10457.
103. Piazzi L., Rampa A., Bisi A., Gobbi S., Belluti F., Cavalli A., Bartolini M., Andrisano V., Valenti P., Recanatini M. 3-(4-[[Benzyl(methyl)amino]methyl]phenyl)-6,7-dimethoxy-2H-2-chromenone (AP2238) inhibits both acetylcholinesterase and acetylcholines-terase-induced beta-amyloid aggregation: a dual function lead for Alzheimer's disease therapy. J. Med. Chem. 2003, 46:2279-2282.
104. Wong D.M., Greenblatt H.M., Dvir H., Carlier P.R., Han Y.F., Pang Y.P., Silman I., Sussman J.L. Acetylcholinesterase complexed with bivalent ligands related to huperzine a: experimental evidence for species-dependent protein-ligand complementarity. J. Am. Chem. Soc. 2003, 125:363-373.
105. Parenti M.A., Hatfield S.M., Leyden J.J. Mupirocin: a topical antibiotic with a unique structure and mechanism of action. Clin. Pharm. 1987, 6:761-770.
106. Poux A.N., Cebrat M., Kim C.M., Cole P.A., Marmorstein R. Structure of the GCN5 histone acetyltransferase bound to a bisubstrate inhibitor. Proc. Natl. Acad. Sci. USA 2002, 99:14065-14070.
107. Parang K., Cole P.A. Designing bisubstrate analog inhibitors for protein kinases. Pharmacol. Ther. 2002, 3:145-157.
108. Spannhoff A., Machmur R., Heinke R., Trojer P., Bauer I., Brosch G., Schule R., Hanefeld W., Sippl W., Jung M. A novel arginine methyltransferase inhibitor with cellular activity. Bioorg. Med. Chem. Lett. 2007, 17:4150-4153.
109. North B.J., Verdin E. Sirtuins: Sir2-related NAD-dependent protein deacetylases. Genome Biol. 2004, 5:224-234.
110. Schafer S., Jung M. Chromatin modifications as targets for new anticancer drugs. Arch. Pharm. (Weinheim) 2005, 338:347-357.
111. Heltweg B., Gatbonton T., Schuler A.D., Posakony J., Li H., Goehle S., Kollipara R., Depinho R.A., Gu Y., Simon J.A., Bedalov A. Antitumor activity of a small-molecule inhibitor of human silent information regulator 2 enzymes. Cancer Res. 2006, 66:4368-4377.
112. +-dependent deacetylase SIRT5 by suramin. Structure, 2007, 15:377-389.
113. Trapp J., Meier R., Hongwiset D., Kassack M.U., Sippl W., Jung M. Structure-activity studies on suramin analogues as inhibitors of NAD(+)-dependent histone deacetylases (sirtuins). Chem. Med. Chem 2007, in press.
114. Tew K.D. Glutathione-associated enzymes in anticancer drug resistance. Cancer Res. 1994, 54:4313-4320.
115. Lyttle M.H., Hocker M.D., Hui H.C., Caldwell C.G., Aaron D.T., Engqvist-Goldstein A., Flatgaard J.E., Bauer K.E. Isozyme-specific glutathione-S-transferase inhibitors: design and synthesis. J. Med. Chem. 1994, 37:189-194.
116. Oakley A.J., Lo Bello M., Ricci G., Federici G., Parker M.W. Evidence for an induced-fit mechanism operating in pi class glutathione transferases. Biochemistry, 1998, 37:9912-9917.
117. Lyon R.P., Hill J.J., Atkins W.M. Novel class of bivalent glutathi-one S-transferase inhibitors. Biochemistry 2003, 42:10418-10428.
118. Drews J. Genomic sciences and the medicine of tomorrow. Nat. Biotechnol. 1996, 14:1516-1518.
119. Milligan G. G protein-coupled receptor dimerization: function and ligand pharmacology. Mol. Pharmacol. 2004, 66:1-7.
120. Rozenfeld R., Decaillot F.M., IJzerman A.P., Devi L.A. Heterodimers of G protein-coupled receptors as novel and distinct drug targets. Drug Discov. Today, 2006, 3:437-443.
121. Palczewski K., Kumasaka T., Hori T., Behnke C.A., Motoshima H., Fox B.A., Le Trong I., Teller D.C., Okada T., Stenkamp R.E., Yamamoto M., Miyano M. Crystal structure of rhodopsin: A G protein-coupled receptor. Science 2000, 289:739-745.
122. Daniels D.J., Kulkarni A., Xie Z., Bhushan R.G., Portoghese P.S. A bivalent ligand (KDAN-18) containing delta-antagonist and kappa-agonist pharmacophores bridges delta2 and kappa1 opioid receptor phenotypes. J. Med. Chem. 2005, 48:1713-1716.
123. Bhushan R.G., Sharma S.K., Xie Z., Daniels D.J., Portoghese P.S. A bivalent ligand (KDN-21) reveals spinal delta and kappa opioid receptors are organized as heterodimers that give rise to delta(1) and kappa(2) phenotypes. Selective targeting of delta-kappa heterodimers. J. Med. Chem. 2004, 47:2969-2972.
124. Jacobson K.A., Xie R., Young L., Chang L., Liang B.T. A novel pharmacological approach to treating cardiac ischemia. Binary conjugates of A1 and A3 adenosine receptor agonists. J. Biol. Chem. 2000, 275:30272-30279.
125. Abadi A.H., Lankow S., Hoefgen B., Decker M., Kassack M.U., Lehmann J. Dopamine/serotonin receptor ligands, part III1: syn-thesis and biological activities of 7, 7'-alkylene-bis-6, 7, 8, 9, 14, 15-hexahydro-5H-benz[d]indolo[2, 3-g]azecines - application of the bivalent ligand approach to a novel type of dopamine receptor antagonist. Arch. Pharm. (Weinheim) 2002, 335:367-373.
126. Bonger K.M., van den Berg R.J., Heitman L.H., AP I.J., Oosterom J., Timmers C.M., Overkleeft H.S., van der Marel G.A. Synthesis and evaluation of homo-bivalent GnRHR ligands. Bioorg. Med. Chem. 2007, 15:4841-4856.
127. Rajeswaran W.G., Cao Y., Huang X.P., Wroblewski M.E., Colclough T., Lee S., Liu F., Nagy P.I., Ellis J., Levine B.A., Nocka K.H., Messer W.S. Design, synthesis, and biological characterization of bivalent 1-methyl-1,2,5,6-tetrahydropyridyl-1,2,5-thiadiazole derivatives as selective muscarinic agonists. J. Med. Chem. 2001, 44:4563-4576.
128. Soulier J.L., Russo O., Giner M., Rivail L., Berthouze M., Ongeri S., Maigret B., Fischmeister R., Lezoualc'h F., Sicsic S., Berque-Bestel I. Design and synthesis of specific probes for human 5-HT4 receptor dimerization studies. J. Med. Chem. 2005, 48:6220-6228.
129. Chini B., Manning M. Agonist selectivity in the oxytocin/vasopressin receptor family: new insights and challenges. Biochem. Soc. Trans. 2007, 35:737-741.
130. Fotiadis D., Jastrzebska B., Philippsen A., Muller D.J., Palczewski K., Engel A. Structure of the rhodopsin dimer: a working model for G-protein-coupled receptors. Curr. Opin. Struct. Biol. 2006, 16:252-259.
131. Russo O., Berthouze M., Giner M., Soulier J.L., Rivail L., Sicsic S., Lezoualc'h F., Jockers R., Berque-Bestel I. Synthesis of specific bivalent probes that functionally interact with 5-HT4 receptor dimers. J. Med. Chem} 2007, in press.
132. Filizola M., Wang S.X., Weinstein H. Dynamic models of G-protein coupled receptor dimers: indications of asymmetry in the rhodopsin dimer from molecular dynamics simulations in a POPC bilayer. J. Comput. Aided Mol. Des. 2006, 20:405-416.